

# WESTERN CANADA URO-ONCOLOGY GROUP (WCUOG) ANNUAL MEETING 2022

DECEMBER 9 – 10, 2022 | VANCOUVER, BC

## PRIMARY OBJECTIVE:

- At the conclusion of this meeting, participants will be able to utilize recent clinical trial data to make best evidence-based decision making in uro-oncology

## BLADDER CANCER SESSION OBJECTIVES:

- Stratify risk of recurrence and progression accurately in patients with non-muscle invasive bladder cancer
- Describe the optimal therapy according to established guidelines for management of intermediate and high-risk non-muscle invasive bladder cancer
- Identify optimal neoadjuvant and adjuvant therapies to maximize outcomes after radical cystectomy

## PROSTATE CANCER SESSION OBJECTIVES:

- Discuss the potential impact of genome-wide association studies that have yielded genetic risk prediction tools
- Describe the state of the evidence related to focal treatment of localized prostate cancer.
- Discuss issues surrounding safety, feasibility and logistics of transrectal and transperineal approaches for diagnostic prostate biopsy
- Review clinical trials evaluating new therapeutic approaches to advanced prostate cancer, including mCSPC, nmCRPC and mCRPC
- Discuss how somatic and germline next generation sequencing results may be integrated into clinical management in patients with advanced prostate cancer

## RENAL CANCER SESSION OBJECTIVES:

- Describe strategies for multi-disciplinary treatment of locally advanced and metastatic kidney cancer
- Recognize treatment approaches for high-risk renal cancer including the role of adjuvant and metastatic renal cell cancer therapies
- Identify the role of nephrectomy in patients with metastatic renal cell carcinoma
- Identify the emerging role of biomarkers for the future management of kidney cancer
- Treatment options for kidney cancer patients



MEETING CHAIR:  
**ALAN SO**  
University of British Columbia

# DECEMBER 2022

<b>09</b>	<b>WELCOME ADDRESS</b>	19:00
<b>FRI</b>	<b>WCUOG ANNUAL LECTURE</b> (State-of-art Lecture)	19:30
	<b>NETWORKING EVENT</b>	20:30

---

<b>10</b>	<b>PROSTATE CANCER SESSION</b>	08:00
<b>SAT</b>	<ul style="list-style-type: none"><li>• Integration of somatic and germline next generation sequencing in clinical practice</li><li>• Focal therapy in prostate cancer and perineal approaches for prostate biopsy</li><li>• Review of recent data in mCSPC</li><li>• Novel therapeutics in mCRPC: new changes in guidelines</li><li>• Prostate Cancer trials update</li></ul>	
	<b>BREAK</b>	10:15
	<b>BLADDER CANCER SESSION</b>	10:30
	<ul style="list-style-type: none"><li>• Describe the optimal therapy according to established guidelines for management of intermediate and high-risk non-muscle invasive bladder cancer</li><li>• Identify optimal neoadjuvant and adjuvant therapies to maximize outcomes after radical cystectomy</li><li>• Review of management of metastatic bladder cancer</li><li>• Bladder cancer trial update</li><li>• Role of Mutli-Disciplinary care in advanced bladder cancer</li></ul>	
	<b>LUNCH</b>	12:30
	<b>KIDNEY CANCER SESSION</b>	13:30
	<ul style="list-style-type: none"><li>• Treatment approaches for high-risk localized renal cancer including the role of adjuvant RCC therapies</li><li>• Identify the role of nephrectomy and metastatectomy in patients with metastatic RCC</li><li>• Review of systemic therapy of RCC: what does a Urologist need to know</li><li>• RCC cancer trial update</li></ul>	
	<b>BREAK</b>	15:15
	<b>IMAGING UPDATE</b>	15:30
	<ul style="list-style-type: none"><li>• Role of MRI in Prostate cancer</li><li>• Advances and Role of PET scanning in Prostate cancer</li></ul>	
	<b>CLOSING REMARKS</b>	16:30

# AGENDA

